<SEC-DOCUMENT>0001102624-15-000572.txt : 20150415
<SEC-HEADER>0001102624-15-000572.hdr.sgml : 20150415
<ACCEPTANCE-DATETIME>20150415105532
ACCESSION NUMBER:		0001102624-15-000572
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20150414
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20150415
DATE AS OF CHANGE:		20150415

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUCELL CORP /DE/
		CENTRAL INDEX KEY:			0000811641
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				010382980
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12934
		FILM NUMBER:		15770859

	BUSINESS ADDRESS:	
		STREET 1:		56 EVERGREEN DR
		CITY:			PORTLAND
		STATE:			ME
		ZIP:			04103
		BUSINESS PHONE:		2078782770

	MAIL ADDRESS:	
		STREET 1:		56 EVERGREEN DRIVE
		CITY:			PORTLAND
		STATE:			ME
		ZIP:			04103
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>immucell8k.htm
<DESCRIPTION>IMMUCELL CORPORATION 8-K
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html>
<head>
 <title>Edgar-8K</title>
 <!-- IMPORTANT NOTE: This form must comply with SEC's requirements for EDGAR online submissions,
 which can be found in "EDGAR Filer Manual (Volume II)" or online at "http://www.sec.gov/info/edgar/edmanuals.htm" -->
</head>

<body>
 <div style="text-align:center;height:20px"> </div>

 <div style="text-align:center;padding:1px;font-weight:bold;" id="header-static-country">UNITED STATES</div>
 <div style="text-align:center;padding:1px;font-weight:bold;" id="header-static-sec">SECURITIES AND EXCHANGE COMMISSION</div>
 <div style="text-align:center;padding:1px" id="header-static-washington">Washington, D.C. 20549</div>
 <hr style="width:350px" size="1" />

 <div style="text-align:center;height:20px"> </div>
 <div style="text-align:center;padding:1px;font-weight:bold;" id="header-static-form">FORM 8-K</div>

 <div style="text-align:center;height:20px"> </div>
 <div style="text-align:center;padding:1px;font-weight:bold;" id="header-static-report">CURRENT REPORT</div>

 <div style="text-align:center;height:20px"> </div>
 <div style="text-align:center;padding:1px;font-weight:bold;" id="header-static-law">Pursuant to Section 13 or 15(d) of the<br />Securities Exchange Act of 1934</div>

 <div style="text-align:center;height:20px"> </div>
 <div style="text-align:center;padding:1px;">
  <font style="font-weight:bold" id="header-label-reportdate">Date of Report: </font>
  <font id="header-field-reportdate">April 14, 2015</font>
 </div>
 <div style="text-align:center;padding:1px;" id="header-static-reportdatecomment">(Date of earliest event reported)</div>

 <div style="text-align:center;height:20px"> </div>
 <div style="text-align:center;padding:1px;font-weight:bold;" id="header-field-companyname">ImmuCell Corporation</div>
 <div style="text-align:center;padding:1px;" id="header-static-companynamecomment">(Exact name of registrant as specified in its charter)</div>

 <div style="text-align:center;height:20px;"> </div>
 <div style="text-align:center;width:100%">
     <table style="margin-left:auto;margin-right:auto;width:80%;">
      <tr>
       <td style="text-align:center;padding:1px;font-weight:bold;width:30%" id="header-field-jurisdiction">DE</td>
       <td style="width:5%"> </td>
       <td style="text-align:center;padding:1px;font-weight:bold;width:30%" id="header-field-commisionfile">001-12934</td>
       <td style="width:5%"> </td>
       <td style="text-align:center;padding:1px;font-weight:bold;width:30%" id="header-field-employerid">01-0382980</td>
      </tr>
      <tr>
       <td style="text-align:center;padding:1px;" id="header-static-jurisdictioncomment">(State or other jurisdiction of incorporation)</td>
       <td> </td>
       <td style="text-align:center;padding:1px;" id="header-static-commisionfilecomment">(Commission File Number)</td>
       <td> </td>
       <td style="text-align:center;padding:1px;" id="header-static-employeridcomment">(IRS Employer Identification Number)</td>
      </tr>
     </table>
 </div>

 <div style="text-align:center;height:20px;"> </div>
 <div style="text-align:center;width:100%">
 <table style="margin-left:auto;margin-right:auto;width:80%;">
  <tr>
   <td style="text-align:center;padding:1px;font-weight:bold;width:45%" id="header-field-address">56 Evergreen Drive, Portland, Maine</td>
   <td style="width:10%"> </td>
   <td style="text-align:center;padding:1px;padding:1px;font-weight:bold;width:45%" id="header-field-zipcode">04103</td>
  </tr>
  <tr>
   <td style="text-align:center;" id="header-static-addresscomment">(Address of principal executive offices)</td>
   <td> </td>
   <td style="text-align:center;" id="header-static-zipcodecomment">(Zip Code)</td>
  </tr>
 </table>
 </div>

 <div style="text-align:center;height:20px"> </div>
 <div style="text-align:center;padding:1px;font-weight:bold;" id="header-field-telephone">2078782770</div>
 <div style="text-align:center;padding:1px;" id="header-static-telephonecomment">(Registrant's telephone number, including area code)</div>

 <div style="text-align:center;height:20px"> </div>
 <div style="text-align:center;padding:1px;font-weight:bold;">Not Applicable</div>
 <div style="text-align:center;padding:1px;">(Former Name or Former Address, if changed since last report)</div>

 <div style="text-align:center;height:20px"> </div>
 <div style="margin-left:auto;margin-right:auto;width:80%;">

     <p>Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following  provisions:</p>
     <table style="margin-left:auto; margin-right:auto; width:80%;">
         <tr>
             <td style="width:20px; text-align:center; vertical-align:middle;">
                 <div id="header-field-rule425" style="width:1.2em; height:1.2em; padding:0; border:solid 1px #000000; font-size:0.8em; text-align:center; font-weight:bold;">&nbsp;</div>
             </td>
             <td style="width:auto;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</td>
         </tr>
         <tr>
             <td style="width:20px; text-align:center; vertical-align:middle;">
                 <div id="Div1" style="width:1.2em; height:1.2em; padding:0; border:solid 1px #000000; font-size:0.8em; text-align:center; font-weight:bold;">&nbsp;</div>
             </td>
             <td style="width:auto;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</td>
         </tr>
         <tr>
             <td style="width:20px; text-align:center; vertical-align:middle;">
                 <div id="Div2" style="width:1.2em; height:1.2em; padding:0; border:solid 1px #000000; font-size:0.8em; text-align:center; font-weight:bold;">&nbsp;</div>
             </td>
             <td style="width:auto;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</td>
         </tr>
         <tr>
             <td style="width:20px; text-align:center; vertical-align:middle;">
                 <div id="Div3" style="width:1.2em; height:1.2em; padding:0; border:solid 1px #000000; font-size:0.8em; text-align:center; font-weight:bold;">&nbsp;</div>
             </td>
             <td style="width:auto;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</td>
         </tr>
     </table>
    </div>

    <hr />

 <div style="margin-left:auto;margin-right:auto;width:80%;" id="body-list-itmes">

     <div style="display:none;">
         <div style="text-align:center;height:20px"> </div>
         <div style="padding:1px;font-weight:bold">Item 1.01. Entry into a Material Definitive Agreement</div>
         <div style="padding:1px;">Item not selected.</div>
     </div>

     <div style="display:none;">
         <div style="text-align:center;height:20px"> </div>
         <div style="padding:1px;font-weight:bold">Item 1.02. Termination of a Material Definitive Agreement</div>
         <div style="padding:1px;">Item not selected.</div>
     </div>

     <div style="display:none;">
         <div style="text-align:center;height:20px"> </div>
         <div style="padding:1px;font-weight:bold">Item 1.03. Bankruptcy or Receivership</div>
         <div style="padding:1px;">Item not selected.</div>
     </div>

     <div style="display:none;">
         <div style="text-align:center;height:20px"> </div>
         <div style="padding:1px;font-weight:bold">Item 1.04. Mine Safety - Reporting of Shutdowns and Patterns of Violations</div>
         <div style="padding:1px;">Item not selected.</div>
     </div>

     <div style="display:none;">
         <div style="text-align:center;height:20px"> </div>
         <div style="padding:1px;font-weight:bold">Item 2.01. Completion of Acquisition or Disposition of Assets</div>
         <div style="padding:1px;">Item not selected.</div>
     </div>

     <div style="display:none;">
         <div style="text-align:center;height:20px"> </div>
         <div style="padding:1px;font-weight:bold">Item 2.02. Results of Operations and Financial Condition</div>
         <div style="padding:1px;">Item not selected.</div>
     </div>

     <div style="display:none;">
         <div style="text-align:center;height:20px"> </div>
         <div style="padding:1px;font-weight:bold">Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant</div>
         <div style="padding:1px;">Item not selected.</div>
     </div>

     <div style="display:none;">
         <div style="text-align:center;height:20px"> </div>
         <div style="padding:1px;font-weight:bold">Item 2.04. Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement</div>
         <div style="padding:1px;">Item not selected.</div>
     </div>

     <div style="display:none;">
         <div style="text-align:center;height:20px"> </div>
         <div style="padding:1px;font-weight:bold">Item 2.05. Costs Associated with Exit or Disposal Activities</div>
         <div style="padding:1px;">Item not selected.</div>
     </div>

     <div style="display:none;">
         <div style="text-align:center;height:20px"> </div>
         <div style="padding:1px;font-weight:bold">Item 2.06. Material Impairments</div>
         <div style="padding:1px;">Item not selected.</div>
     </div>

     <div style="display:none;">
         <div style="text-align:center;height:20px"> </div>
         <div style="padding:1px;font-weight:bold">Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing</div>
         <div style="padding:1px;">Item not selected.</div>
     </div>

     <div style="display:none;">
         <div style="text-align:center;height:20px"> </div>
         <div style="padding:1px;font-weight:bold">Item 3.02. Unregistered Sales of Equity Securities</div>
         <div style="padding:1px;">Item not selected.</div>
     </div>

     <div style="display:none;">
         <div style="text-align:center;height:20px"> </div>
         <div style="padding:1px;font-weight:bold">Item 3.03. Material Modification to Rights of Security Holders</div>
         <div style="padding:1px;">Item not selected.</div>
     </div>

     <div style="display:none;">
         <div style="text-align:center;height:20px"> </div>
         <div style="padding:1px;font-weight:bold">Item 4.01. Changes in Registrant's Certifying Accountant</div>
         <div style="padding:1px;">Item not selected.</div>
     </div>

     <div style="display:none;">
         <div style="text-align:center;height:20px"> </div>
         <div style="padding:1px;font-weight:bold">Item 4.02. Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review</div>
         <div style="padding:1px;">Item not selected.</div>
     </div>

     <div style="display:none;">
         <div style="text-align:center;height:20px"> </div>
         <div style="padding:1px;font-weight:bold">Item 5.01. Changes in Control of Registrant</div>
         <div style="padding:1px;">Item not selected.</div>
     </div>

     <div style="display:none;">
         <div style="text-align:center;height:20px"> </div>
         <div style="padding:1px;font-weight:bold">Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers</div>
         <div style="padding:1px;">Item not selected.</div>
     </div>

     <div style="display:none;">
         <div style="text-align:center;height:20px"> </div>
         <div style="padding:1px;font-weight:bold">Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year</div>
         <!--<div style="padding:1px;">
             <font>End of Fiscal Year: </font><font></font>
         </div>-->
         <div style="padding:1px;">Item not selected.</div>
     </div>

     <div style="display:none;">
         <div style="text-align:center;height:20px"> </div>
         <div style="padding:1px;font-weight:bold">Item 5.04. Temporary Suspension of Trading Under Registrant's Employee Benefit Plans</div>
         <div style="padding:1px;">Item not selected.</div>
     </div>

     <div style="display:none;">
         <div style="text-align:center;height:20px"> </div>
         <div style="padding:1px;font-weight:bold">Item 5.05. Amendment to Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics</div>
         <div style="padding:1px;">Item not selected.</div>
     </div>

     <div style="display:none;">
         <div style="text-align:center;height:20px"> </div>
         <div style="padding:1px;font-weight:bold">Item 5.06. Change in Shell Company Status</div>
         <div style="padding:1px;">Item not selected.</div>
     </div>

     <div style="display:none;">
         <div style="text-align:center;height:20px"> </div>
         <div style="padding:1px;font-weight:bold">Item 5.07. Submission of Matters to a Vote of Security Holders</div>
         <div style="padding:1px;">Item not selected.</div>
     </div>

     <div style="display:none;">
         <div style="text-align:center;height:20px"> </div>
         <div style="padding:1px;font-weight:bold">Item 5.08. Shareholder Nominations Pursuant to Exchange Act Rule 14a-11</div>
         <div style="padding:1px;">Item not selected.</div>
     </div>

     <div style="display:none;">
         <div style="text-align:center;height:20px"> </div>
         <div style="padding:1px;font-weight:bold">Item 6.01. ABS Informational and Computational Materials</div>
         <div style="padding:1px;">Item not selected.</div>
     </div>

     <div style="display:none;">
         <div style="text-align:center;height:20px"> </div>
         <div style="padding:1px;font-weight:bold">Item 6.02. Change of Servicer or Trustee</div>
         <div style="padding:1px;">Item not selected.</div>
     </div>

     <div style="display:none;">
         <div style="text-align:center;height:20px"> </div>
         <div style="padding:1px;font-weight:bold">Item 6.03. Change in Credit Enhancement of Other External Support</div>
         <div style="padding:1px;">Item not selected.</div>
     </div>

     <div style="display:none;">
         <div style="text-align:center;height:20px"> </div>
         <div style="padding:1px;font-weight:bold">Item 6.04. Failure to Make a Required Distribution</div>
         <div style="padding:1px;">Item not selected.</div>
     </div>

     <div style="display:none;">
         <div style="text-align:center;height:20px"> </div>
         <div style="padding:1px;font-weight:bold">Item 6.05. Securities Act Updating Disclosure</div>
         <div style="padding:1px;">Item not selected.</div>
     </div>

      <div style="display:none;">
         <div style="text-align:center;height:20px"> </div>
         <div style="padding:1px;font-weight:bold">Item 6.06. Static Pool</div>
         <div style="padding:1px;">Item not selected.</div>
     </div>

     <div style="display:none;">
         <div style="text-align:center;height:20px"> </div>
         <div style="padding:1px;font-weight:bold">Item 6.10. Alternative Filings of Asset-Backed Issuers</div>
         <div style="padding:1px;">Item not selected.</div>
     </div>

     <div style="display:none;">
         <div style="text-align:center;height:20px"> </div>
         <div style="padding:1px;font-weight:bold">Item 7.01. Regulation FD Disclosure</div>
         <div style="padding:1px;">Item not selected.</div>
     </div>

     <div style="">
         <div style="text-align:center;height:20px"> </div>
         <div style="padding:1px;font-weight:bold">Item 8.01. Other Events</div>
         <div style="padding:1px;">On April 14, 2015, ImmuCell Corporation (the &quot;Company&quot;) amended its Common Stock Rights Plan. This amendment is discussed in greater detail in today's press release, which is attached as Exhibit 99.1 to this Current Report on Form 8-K.<br /><br />The information shall not be deemed &quot;filed&quot; for purposes of Section 18 of the Securities Exchange Act of 1934 (the &quot;Exchange Act&quot;) or otherwise subject to liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.   <br /></div>
     </div>

     <div style="">
         <div style="text-align:center;height:20px"> </div>
         <div style="padding:1px;font-weight:bold">Item 9.01. Financial Statements and Exhibits</div>
         <div style="padding:1px;"></div>

         <div style="display:none;">
             <div style="text-align:center;height:20px"> </div>
             <div style="padding:1px;font-weight:bold">(a) Financial statements:</div>
             <div style="padding:1px;">None</div>
         </div>

         <div style="display:none;">
             <div style="text-align:center;height:20px"> </div>
             <div style="padding:1px;font-weight:bold">(b) Pro forma financial information:</div>
             <div style="padding:1px;">None</div>
         </div>

         <div style="display:none;">
             <div style="text-align:center;height:20px"> </div>
             <div style="padding:1px;font-weight:bold">(c) Shell company transactions:</div>
             <div style="padding:1px;">None</div>
         </div>

         <div style="">
             <div style="text-align:center;height:20px"> </div>
             <div style="padding:1px;font-weight:bold">(d) Exhibits</div>
             <div style="padding:1px;"><a href="exhibit99.htm" id="body-field-exhibits">Press Release of <font>ImmuCell Corporation dated April 15, 2015</font></a></div>
         </div>
     </div>
 </div>

 <hr />

 <div style="text-align:center;height:20px"> </div>
 <div style="text-align:center;margin-left:auto;margin-right:auto;width:80%;">
  <div style="text-align:center;padding:1px;font-weight:bold;">Signature</div>
  <p>Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>
  <table style="width:100%">
   <tr>
    <td style="width:30%;text-align:left">
     <font>Dated: </font><font id="signature-field-date">April 15, 2015</font>
    </td>
    <td style="width:40%"> </td>
    <td style="width:30%;text-align:left">
     <font style="font-weight:bold" id="signature-field-company">ImmuCell Corporation</font><br /><br />
     <font>By: </font><font style="text-decoration:underline" id="signature-field-signature">/s/ Michael F. Brigham </font><br />
     <font> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font id="signature-field-signaturename">Michael F. Brigham </font><br />
     <font> &nbsp;&nbsp;&nbsp&nbsp;&nbsp;</font><font style="font-style:italic"id="signature-field-signaturetitle">President, Chief Executive Officer and Principal Financial Officer</font>
    </td>
   </tr>
  </table>
 </div>

 <hr />

 <div style="text-align:center;height:20px"> </div>
 <div style="text-align:center;padding:1px;font-weight:bold;" id="header-static-exhibitindex">Exhibit Index</div>

 <table style="margin-left:auto;margin-right:auto;width:80%;">
  <tr>
   <td style="text-align:center;text-decoration:underline;padding:1px;font-weight:bold;width:35%" id="footer-label-exhibitno">Exhibit No.</td>
   <td style="width:30%"> </td>
   <td style="text-align:center;text-decoration:underline;padding:1px;font-weight:bold;width:35%" id="footer-label-description">Description</td>
  </tr>
  <tr>
   <td style="text-align:center;padding:1px;" id="footer-field-exhibitno">99.1</td>
   <td> </td>
   <td style="text-align:center;padding:1px;" id="footer-field-exhibitdescription">Press Release of <font>ImmuCell Corporation dated April 15, 2015</font></td>
  </tr>
 </table>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>exhibit99.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<p></p>
<b>ImmuCell Board of Directors Amends Its Common Stock Rights Plan</b>
<p>
PORTLAND, ME -- (Marketwired - April 15, 2015) - ImmuCell Corporation (NASDAQ: ICCC) today announced that its Board of Directors has voted to amend its Common Stock Rights Plan (Rights Plan).
</p>

<p>
The Rights Plan was first implemented in 1995 and has been amended and extended several times since then. The details of the Rights Plan are set forth in a Rights Agreement between the Company and American Stock Transfer & Trust Co., as Rights Agent.
</p>

<p>
One provision in the Rights Plan, commonly known as a "dead hand provision", prevented a new group of directors elected following the emergence of an Acquiring Person (an owner of more than 20% of ImmuCell's stock) from controlling the Rights Plan by maintaining exclusive authority over the Rights Plan with the pre-existing directors. Subsequent to the adoption of the Rights Plan, such provisions have come to be viewed with disfavor by the Delaware courts.
</p>

<p>
On April 14, 2015, ImmuCell's Board of Directors voted to authorize its management in consultation with legal counsel, to take all necessary and appropriate action to remove the Dead Hand Provision from the Rights Plan.
</p>

<p>
"We simply feel that the most efficient use of our time and resources is to make this amendment to the Rights Plan to prevent a debate about its merits from distracting us from our most pressing business and strategic initiatives," commented Michael F. Brigham, President and CEO.
</p>

<p>
About ImmuCell
</p>
<p>
ImmuCell Corporation's (NASDAQ: ICCC) purpose is to create scientifically-proven and practical products that improve animal health and productivity in the dairy and beef industries. ImmuCell has developed products that provide significant, immediate immunity to newborn dairy and beef cattle. The Company has also developed products that address mastitis, the most significant cause of economic loss to the dairy industry. Press releases and other information about the Company are available at our website, (http://www.immucell.com).
</p>

<p>
Safe Harbor Statement
</p>
<p>
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to: projections of future financial performance; the scope and timing of future product development work and commercialization of our products; future costs of product development efforts; the estimated prevalence rate of subclinical mastitis; future market share of and revenue generated by products still in development; future sources of financial support for our product development, manufacturing and marketing efforts; the future adequacy of our own manufacturing facilities or those of third parties with which we have contractual relationships to meet demand for our products on a timely basis; the amount and timing of future investments in facility modifications and production equipment; the future adequacy of our working capital and the availability of third party financing; timing and future costs of a facility to produce the Drug Substance (active pharmaceutical ingredient) for Mast Out(R); the timing and outcome of pending or anticipated applications for future regulatory approvals; future regulatory requirements relating to our products; future expense ratios and margins; future compliance with bank debt covenants; future realization of deferred tax assets; costs associated with sustaining compliance with cGMP regulations in our current operations and attaining such compliance for the facility to produce the Drug Substance for Mast Out(R); factors that may affect the dairy and beef industries and future demand for our products; the cost-effectiveness of additional sales and marketing expenditures and resources; the accuracy of our understanding of our distributors' ordering patterns; anticipated changes in our manufacturing capabilities and efficiencies; anticipated competitive and market conditions; and any other statements that are not historical facts. Forward-looking statements can be identified by the use of words such as "expects", "may", "anticipates", "aims", "intends", "would", "could", "should", "will", "plans", "believes", "estimates", "targets", "projects", "forecasts" and similar words and expressions. In addition, there can be no assurance that future developments affecting us will be those that we anticipate. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to difficulties or delays in development, testing, regulatory approval, production and marketing of our products, competition within our anticipated product markets, alignment between our manufacturing resources and product demand, the uncertainties associated with product development and Drug Substance manufacturing, our potential reliance upon third parties for financial support, products and services, changes in laws and regulations, decision making by regulatory authorities, currency fluctuations and other risks detailed from time to time in filings we make with the Securities and Exchange Commission, including our Quarterly Reports on Form 10-Q, our Annual Reports on Form 10-K and our Current Reports on Form 8-K. Such statements are based on our current expectations, but actual results may differ materially due to various factors.
</p>

<pre>
Contact:
Michael F. Brigham
President and CEO
ImmuCell Corporation
(207) 878-2770

Joe Diaz, Robert Blum and Joe Dorame
Lytham Partners, LLC
(602) 889-9700
ICCC@lythampartners.com</pre>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
